澳大利亚通用诊所注册医师对严重月经出血的特兰克萨姆酸处方的时间趋势
Kristen Hamilton1, Parker Magin2, Amanda Tapley3
1BBiomed, MD, DRANZCOG, FRACGP, Lecturer, Department of General Practice and Primary Care Research, The University of Notre Dame, Sydney, NSW; General Practitioner, Glebe Family Medical Practice, Sydney, NSW.
Australian journal of general practice
|December 2, 2025
概括
澳大利亚的通用医疗注册机构越来越多地为严重的月经出血 (HMB) 处方特兰胺酸 (TXA),这表明对基于证据的指导方针的积极反应. 然而,监管机构的商可能会减缓这种采用.
科学领域:
- 一般实践 一般实践
- 药理学 药理学是指药理学的学科.
- 妇女健康 妇女健康
背景情况:
- 严重的月经出血 (HMB) 显著影响生活质量,缺铁和贫血.
- 特兰胺酸 (TXA) 在HMB管理中表现出比口服激素药物 (OHM) 更高的疗效.
- 基于证据的处方对于优化HMB患者的治疗结果至关重要.
研究的目的:
- 从2010年到2023年,分析澳大利亚通用实践注册机构中TXA对HMB的时间处方趋势.
- 为了比较这个队列中TXA与OHM对HMB的处方模式.
主要方法:
- 利用来自注册员在培训中的临床接触 (ReCEnT) 开始队列研究的横截面分析.
- 使用多变量混合物流回归模型来评估处方趋势.
- 包括来自4717名注册商的数据,响应率为93.4%.
主要成果:
- 对HMB的TXA处方的调整后几率每年增加12% (OR1.12,P=0.004).
- 与OHM相比,TXA的处方每年增加18% (OR 1.18,P=0.019).与OHM相比,TXA的处方每年增加18% (OR 1.18,P=0.019).
- 咨询监事的注册员不太可能比OHM处方TXA (OR 0.36,P=0.034).
结论:
- 越来越多的TXA处方率表明注册机构正在采用基于证据的HMB实践.
- 监管机构实施证据的潜在延误需要进一步调查.
- 结果为促进基于证据的处方在HMB的一般实践中的策略提供了信息.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
01:22Hormonal Regulation of the Menstrual Cycle
1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:30Venous Thrombosis IV: Nursing Management
185
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
185
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K